How are implementers updating results? How will you contact patients? Are you doing clinician education?
One consideration is ACMG Policy statement on patient re-contact after revision of genomic test results.
While not directed at pharmacogenetic test results specifically, several points are applicable. Some keys in my opinion:
Based on the principle of beneficence, an ethical obligation exists to at least attempt to re-contact the patient in circumstances that may meaningfully alter medical care (i.e. change in pharmacogenetic phenotype where prescribing recommendations would differ?)
Re-contact is a shared responsibility among providers, the laboratories, and patients
The discussion regarding re-contact should be documented in the medical record, meaning a discussion should therefore take place with the patient about the possibility of re-contact. Formal re-contact policies may be recommended and should be provided to patients.
For those looking for more information about the CPIC CYP2D6 genotype to phenotype standardization project, it is available on the CPIC Resources page here.